RDIF, Panacea Biotech launch production of Sputnik V vaccine in India; to produce 100 million doses per year
RDIF and Panacea Biotec have launched the production of Sputnik V vaccine in India. India’s Panacea Biotec will now produce 100 million doses of Sputnik V per year.
In August 2020, Russia grew to become the world’s first nation to register a coronavirus vaccine, Sputnik V.
Subsequently, in September, Dr Reddy’s and RDIF entered right into a partnership to conduct scientific trials of Sputnik V, which is developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.
Dr Reddy’s, which had obtained over two lakh vaccines from RDIF, just lately soft-launched Sputnik V and tied up with Apollo Hospitals for piloting the vaccine.
Dr Reddy’s Laboratories has obtained approval from the Indian drug regulator for restricted emergency use of Sputnik V.
